Metastatic breast cancer is the most advanced phase of breast cancer. Women who are usually diagnosed with this disease have seen their cancer spread from the breast into other parts of their body. There are various treatment options available today for women with this disease, which includes chemotherapy, which continues to perform a central role in the treatment of metastatic breast cancer.
However, particular chemotherapy treatments-most notably taxanes, which are one of the most commonly used types of chemotherapy for breast cancer-must be combined with chemical solvents to be delivered into the person's body. As a result, it can take a long time (in some cases up to 3 hours) for a patient to receive her chemotherapy. Additionally, chemical substance solvents can cause serious side effects such as allergic reactions, low blood pressure, rash and shortness of breath, among others. In turn, this could prevent individuals from completing their therapy.
Offering a Different Approach
technology has yielded a different approach to treating metastatic breast cancer with a taxane chemotherapy that is free of solvents. Abraxane for Injectable suspension system (paclitaxel protein-bound particles with regard to injectable suspension) (albumin bound), the only solvent-free taxane radiation treatment, uses an unique technology to enable the delivery of the anti-cancer drug paclitaxel. This unique technologies is based on a human protein known as albumin, which is a natural provider of nutrients throughout the entire body.
"Women diagnosed with metastatic breast cancer may not know that they have options concerning which chemotherapy they get, " commented Virginia Kaklamani, M. D., DSc, associate professor Division of Hematology/ Oncology, Northwestern University. "It is important that women with this disease speak with their doctor about their treatment options, which may include solvent-free taxane chemotherapy. "
The oughout. S. Food & medication Administration approved Abraxane within January 2005 for the treatment of breast cancer after failure associated with combination chemotherapy for metastatic disease or relapse inside six months of adjuvant radiation treatment. Prior therapy should have incorporated anthracycline unless medically contraindicated.
"Abraxane is the just solvent-free taxane chemotherapy approved by the FDA for the treatment of metastatic breast cancer. Abraxane provides an essential option for patients with this illness, " added Dr. Kaklamani.
The most serious adverse occasions associated with Abraxane in the randomized metastatic breast cancer study for which food and drug administration approval was based incorporated neutropenia, anemia, infections, physical neuropathy, nausea, vomiting, plus myalgia/arthralgia. Other common adverse reactions included anemia, asthenia, diarrhea, ocular/visual disturbances, fluid preservation, alopecia, hepatic dysfunction, mucositis, and renal dysfunction.
technology has yielded a different approach to treating metastatic breast cancer, with a taxane chemotherapy that is free of chemical substance solvents.
Important Safety info & Boxed Warning
You should receive Abraxane for Injectable Suspension (paclitaxel protein-bound contaminants for injectable suspension) under the care of a doctor who is trained to use cancer drugs. Because you may have side effects from your therapy, you should get this medicine in a clinic or hospital along with doctors, nurses and pharmacists who are trained to give malignancy drugs.
Abraxane therapy should not be given to patients with metastatic breast cancer who have low white bloodstream cell counts, which may make you more likely to get an infection. Your doctor will schedule frequent bloodstream tests for you in order to check for low blood counts.
notice: Abraxane is paclitaxel made with the human blood protein ?ggehvidestof. This makes it behave differently in the body than regular paclitaxel. DO NOT SUBSTITUTE FOR OR WITH OTHER PACLITAXEL DRUGS.
Important Safety Information
One of the more important side effects associated with chemotherapy is neutropenia, which is a decrease in the number of infection-fighting white-colored blood cells (neutrophils). Normal amounts range from approximately 1, five hundred cells/mm3 to 1, 800 cells/mm3 (but vary according to a number of factors, such as age plus race). If levels drop below 500 cells/mm3, your own risk of developing an infection raises and treatment may be disrupted. To avoid the risk of serious contamination and fever, your doctor will certainly monitor your absolute neutrophil count (ANC) during treatment.
Women should avoid becoming pregnant while being treated with Abraxane. Tell your doctor if you are expecting, if you become pregnant, or you plan to become pregnant while taking Abraxane. Discuss with your doctor how Abraxane may affect fertility. medical a baby while taking Abraxane is not recommended because the medication may be present in breast dairy.
In the randomized metastatic breast cancer research, the most important adverse events incorporated lower white and red blood cellular counts, infections, tingling plus numbness, nausea, vomiting, diarrhea, muscle and joint pains, and mouth sores. Other adverse reactions included weakness, visual disruptions, fluid retention, hair loss, plus liver and kidney disorder. Low platelet counts, allergic reactions (which in rare cases had been severe), cardiovascular reactions, plus injection site reactions had been uncommon.
Sensory neuropathy (numbness, tingling, or burning in the hands and feet) can occur with Abraxane and other paclitaxel medications. Severe sensory damaged nerves can improve with appropriate management, as prescribed by your doctor. You should tell your health professional or doctor if you encounter numbness, tingling, or burning up in your hands or ft while taking Abraxane.
make sure you talk to your doctor or health professional if you have questions regarding the possible side effects of Abraxane treatment.
Abraxane is marketed under a copromotion agreement between Abraxis BioScience, Inc. and AstraZeneca.
Abraxis Oncology is a division of Abraxis BioScience, Inc. almost all Abraxis BioScience, Inc. business names, names of solutions, and names of products referred to herein are trade titles, service marks, and/or art logos that are owned by or even licensed to Abraxis BioScience, its divisions or the affiliates, unless otherwise mentioned.
Post a Comment